InTechOpen uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » "Antioxidant-Antidiabetic Agents and Human Health", book edited by Oluwafemi Oguntibeju, ISBN 978-953-51-1215-0, Published: February 5, 2014 under CC BY 3.0 license. © The Author(s).

Chapter 10

Plants with Hypolipidaemic Effects from Nigerian Flora

By Ngozi Justina Nwodo, Charles Okeke Nnadi, Akachukwu Ibezim and Chika John Mbah
DOI: 10.5772/57181

Article top

Plants with Hypolipidaemic Effects from Nigerian Flora

Ngozi Justina Nwodo, Charles Okeke Nnadi, Akachukwu Ibezim and Chika John Mbah

1. Introduction

Definition: Hyperlipidemia is a heterogeneous group of disorders characterized by high level of lipids (fats) in the bloodstream. These lipids include cholesterol, cholesterol esters, phospholipids, and triglycerides. Lipids are transported in the blood as large 'lipoproteins'. Alternatively, the disease refers to elevated levels of lipids and cholesterol in the blood, or the manifestations of different disorders of lipoprotein metabolism (dyslipidemia).

Causes: Hyperlipidemia could be caused by: (i) Familial combined hypercholesterolemia (ii) Familial hypertriglyceridemia (iii) other disease states such as insulin and non-insulin dependent diabetes mellitus, hypothyroidism, Cushing's syndrome, dysproteinemias, nephrotic syndrome and renal failure, cholestatic disorders and low thyroid (iv) drugs such as anabolic steroids, beta-blockers, birth control pills and estrogens, corticosteroids, protease inhibitors, retinoids, thiazide diuretics (v) diets like cholesterol intake greater than 300 mg per day, fat intake per total calories greater than 40 %, saturated fat intake per total calories greater than 10 % (vi) life style involving habitual excessive alcohol use, lack of exercise, smoking (vii) risk factors such as advancing age, sex (male), stress and postmenopause.

Classification: Lipoproteins are divided into five major classes, based on density and they include: (i) chylomicrons (ii) very low-density lipoproteins (VLDL) (iii) intermediate-density lipoproteins (IDL) (iv) low-density lipoproteins (LDL) and (v) high-density lipoproteins (HDL). Most triglyceride is transported in chylomicrons or VLDL, while most cholesterol is carried in LDL and HDL. Hyperlipidemia, a major, modifiable risk factor for atherosclerosis and cardiovascular disease, including coronary heart disease (CHD) is classified under (1) Primary hyperlipidemias - are probably genetically based, but the genetic defects are known for only a minority of patients. Examples are (i) primary chylomicronemia- recessive traits of deficiency of lipoprotein lipase or its cofactor (ii) familial hypercholesterolemia- an autosomal dominant trait, although levels of LDL tend to increase with normal VLDL; familial combined (mixed) hyperlipoproteinemia- elevated levels of VLDL, LDL (iii) familial dysbetalipoproteinemia-increased LDL with increased TG and cholesterol levels (iv) familial hypertriglyceridemia-increased VLDL production with normal or decreased LDL (v) familial mixed hypertriglyceridemia-serum VLDL and chylomicrons are increased. (2) Secondary hyperlipidemia- results from disease states such as Cushing's syndrome, diabetes, liver disorders, renal disorders, thyroid disease, obesity, as well as alcohol consumption, estrogen administration, and other drug-associated changes in lipid metabolism.

Symptoms: Hyperlipidemia usually does not cause symptoms. Very high levels of lipids or triglycerides can cause yellowish nodules of fat in the skin beneath eyes, elbows and knees, and in tendons (xanthomas). Sometimes pain, swelling of organs such as the liver, spleen or pancreas (pancreatitis) or whitish rings around the eye's iris occur. Diagnosis: Diagnosis is typically based on medical history, physical examination and most importantly blood test done after overnight fasting. The blood test, measure the levels of lipids in the blood and consist of, a fasting blood test for total cholesterol (TC), LDL (bad cholesterol), HDL (good cholesterol), triglycerides (TG). American Cholesterol Education Program advises that lipids be checked at least once every five years, starting at age 20. However, more frequent or earlier testing is recommended if family history of hyperlipidemia; risk factor or disease that may cause hyperlipidemia; complication that may result from hyperlipidemia exist. Also, the American Academy of Pediatrics recommends lipid screening for children at risk (example, a family history of hyperlipidemia and/or diabetes). Table 1 provides specifications for making a determination.

Cholesterol level Acceptable Borderline High
Total Cholesterol (mg/dl)<170 170 – 199 ≥ 200
LDL Cholesterol (mg/dl) <110 110 – 129 ≥ 130
HDL Cholesterol (mg/dl) <4040-59≥ 60
Total glycerides (mg/dl) <150150-200≥ 200

Table 1.

Classification of cholesterol level

Prevalence: (i) A significant percentage of world population has an increased plasma lipid level, resulting in increased risk of coronary heart disease (ii) Ethnic groups adopting a 'western' lifestyle tend to have higher levels of plasma lipids (iii) Men >30 years and women >55 years (in the U.S.) have10 % rise in fasting triglyceride level >200 mg/dl (iv) Severe hypertriglyceridemia (>2000 mg/dl) higher in diabetic patients or patients suffering alcoholism (iv) Lipoprotein lipase deficiency prevalence is much higher in Quebec, Canada. (v) total C and LDL-C rise steadily about 20% in men aged 20 to 50 years, 30% in women aged 20 to 60 years and younger women have lower levels than men while homozygous familial hypercholesterolemia manifests itself from birth (vii) hyperlipidermia is higher among men than women (gender factor) (viii) total cholesterol and LDL-C levels are similar in whites and blacks, triglycerides are lower and HDL-C levels tend to be higher in the African-American population. Asian-Indians have the highest risk, Europeans have an intermediate risk while Chinese have the lowest risk (race factor) (ix) familial combined hyperlipidemia inheritance is autosomal dominant and likely to involve one of multiple enetic defects, familial hypertriglyceridemia is most likely inherited as an autosomal dominant defect, lipoprotein lipase deficiency and hepatic lipase deficiency are very rare autosomal recessive conditions hypercholesterolemia in the majority of the general public is attributed to high-fat diets and poorly understood susceptibility and modifier genes (genetics factor). Published data on the prevalence of lipid abnormalities in Nigeria are scanty. This could be attributed to low prevalence of hyperlipidemia in Nigeria prior to occidental lifestyle. Osuji et al, 2012, reported that the current state of dyslipidemia in Nigeria clearly contradicts the previous perceptions. In their report, dsylipidemia was found to be highly prevalent in Nigeria with consistent low HDL-cholesterol and high LDL-c especially amongst the upper social class and people with other risk factors. Other studies reported low HDL-c, with TC/HDL-c to be prevalent in the Northern part of the country while high prevalence of TC, TG and low HDL were observed in the Southern part of the country amongst people of upper social class.

2. Treatment

Dietary intervention: is the primary treatment strategy, but drug therapy may often be added later to augment treatment. The main component of a “heart-healthy” diet is a food pattern that is low in saturated fat and dietary cholesterol and provides adequate energy to support growth and maintain an appropriate weight. Specific dietary recommendations include: (i) decreased intakes of saturated fat- most effective in lowering LDL. Sources include stick margarine, partially hydrogenated oils and fats, hydrogenated peanut butters, commercial bakery products, commercial fried food (e.g., French fries) and high fat animal products (ii) decreased intakes of trans-fatty acids- trans-fatty acids are thought to increase LDL levels nearly as much as saturated fat and appear to lower HDL. (iii) decreased intakes of dietary cholesterol- lead to LDL reduction. Diabetic patients tend to be more sensitive to dietary cholesterol intake, which is only found in animal products (iv) balance the fatty acid composition of diet- polyunsaturated and monounsaturated fatty acids can lower LDL and could be good substitutes for saturated fats (v) increased fiber intakes- soluble fiber can contribute to LDL reduction and is now a formal part of hyperlipidemia dietary recommendations. Common sources of fiber include oats, psyllium, guar gum, pectin, barley, dried beans, fruits, vegetables, cereals, whole grains, and legumes are good sources of soluble fiber (vi) encourage antioxidant food sources such as carotenoids, vitamins C and E and antioxidant-rich foods such as whole grains, citrus fruits, melons, berries and leafy green vegetables rather than supplements (vii) reduce serum homocysteine levels- adequate intakes of folate and vitamins B6 and B12 as well as total fat restriction may keep homocysteine levels low. Food sources of these nutrients include fruits, dark green and leafy vegetables, fortified cereals, whole grains, lean meats and poultry.

Drug Therapy: Currently, there are many classes of medications that may be utilized in the pharmacologic management of hyperlipidemia. They are (1) HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors (statins). The cornerstone of the lipid-lowering therapy in adults has rested with the HMG CoA reductase inhibitors or statins. The use of these drugs has resulted in important reductions in overall cardiovascular morbidity and mortality. Mechanism of action- reduction of cholesterol synthesis in liver; inhibiting the rate-limiting step in endogenous cholesterol synthesis; compensatory increase in synthesis of LDL receptors on hepatic and extra hepatic tissues; increase in hepatic uptake of circulating LDL which decreases plasma LDL cholesterol; increase in HDL, decrease in TGs and vasodilatation and decrease in atherosclerosis. Pharmacological indication: Clinically used in the treatment of all types of hyperlipidemia except those who are homozygous for familial hypercholesterolemia (lack of LDL receptors). Table 2 summarizes the statins and their clinically applications.

Drug Starting Dose
FDA-Approved Maximum (mg) Half-life
Average Decrease in
LDL-C Per Dose (mg:%)
Atorvastatin (lipitor)10-208014 or 20-3010:39
Fluvastatin (Lescol)2080320:22
Lovastatin (Mevacor)2080220:28
Pitavastatin (Livalo)24122:36
Pravastatin (Pravachol)4080240:34
Rosuvastatin (Crestor)5-1040195:45
Simvastatin (Zocor)2080420:38
Simvastatin/Ezetimibe (Vytorin)10/1010/402210/10:45

Table 2.


(2) Fibrates (activators of lipoprotein lipase): Mechanism of action- agonists at peroxisome proliferator-activated receptor (PPAR); hydrolysis of VLDL and chylomicrons; decrease in serum TGs; increase clearance of LDL by liver and increase in HDL and expression of genes responsible for increased activity of plasma lipoprotein lipase enzyme. Pharmacological indication: most effective in reduction TGs (hypertriglyceridemia); combined hyperlipidemia (type III) if statins are contraindicated. Typical examples are fenofibrate(prodrug) and gemfibrozil (lopid) (3) Ezetimibe: Mechanism of action- inhibits intestinal cholesterol and related phytosterol absorption; decrease in concentration of intrahepatic cholesterol; increase in uptake of circulating LDL; decrease in serum LDL cholesterol levels and compensatory increase in LDL receptors. Pharmacological indication: Effective in hypercholesterolemia together with statins and diet regulation; utilization of ezetimibe along with a statin allows for lower doses of the statin to be used, therefore reducing the likelihood of dose-related side effects of the statin. (4) Nicotinic acid; Niacin (Inhibitor of lipolysis): Mechanism of action- a potent inhibitor of lipolysis in adipose tissues; decreases mobilization of FFAs (major precursor of TGs) to the liver; increases HDL levels; decreases LDL, decreases endothelial dysfunction and thrombosis. Pharmacological indication- Used in the treatment of familial hyperlipidemias (type IIB) (increase in VLDL and LDL); combined with fibrates or cholestyramine in the treatment of hypercholesterolemia (5) Bile acids- Sequestrants(resins): The bile acid binding resins have been felt to be preferred in the pediatric age group as they are not systemically absorbed. Mechanism of action- are anion exchange resins; bind bile acids in the intestine forming complex that leads to loss of bile acids in the stools; increase the conversion of cholesterol into bile acids in the liver; compensatory increase in LDL receptors leading to decreased concentration of intrahepatic cholesterol; increase hepatic uptake of circulating LDL and decrease serum LDL cholesterol levels. Pharmacological indication: Effective in the treatment of type IIA and IIB hyperlipidemias (along with statins when response to statins is inadequate or they are contraindicated); treatment of pruritus in biliary obstruction (as rising from increase in bile acids). Typical examples are cholestyramine, colestipol and colesevelam. (6) Lovaza (Omega-3-acid ethyl ester): Mechanism of action: is unclear; however, proposed mechanisms include decreasing lipogenesis in the liver, increasing plasma lipoprotein lipase activity, and increasing mitochondrial and perixosomal lipase activity. The drug may increase aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and has also been known to prolong bleeding time. Pharmacological indication: is indicated as adjunct therapy to diet in patients with triglyceride levels greater than or equal to 500 mg/dl (hypertriglyceridemia). It provides significant reduction in triglycerides, of approximately 44.9%, making it an ideal drug choice in patients with high triglycerides (7) Fish oil is another common over-the-counter (OTC) product that provides an alternative to the prescription product Lovaza (8) OTC herbal product: (i) Red yeast rice (RYR)- herbal supplements used for lipid-lowering effects. RYR is obtained by fermenting Monascus purpureus, a form of yeast, on rice, which is then dried, pulverized, and encapsulated. This process leads to the formation of 14 monacolins, which are compounds that inhibit HMG-CoA reductase. One of the mona-colins, monacolin K (lovastatin or mev-inolin) was the first synthesized HMG-CoA reductase inhibitor. RYR is commercially available in 600-mg capsules (ii) Plant sterols and stanols also assist in the reduction of LDL-C. Plant sterols reduce cholesterol absorption by competing with cholesterol for space within bile salt micelles in the intestinal lumen. The plant stanols, which are the result of the hydrogenation of sterols, are not absorbed as well as sterols. Ingestion of about 2 g per day of plant sterols or stanols, produces LDL-C reduction of 6% to 15%. Prevention: Cardiovascular disease (CVD) is the leading cause of mortality in advance countries, with hyperlipidemia a common risk factor for CVD, in adults having abnormal cholesterol values and elevated low-density lipoprotein (LDL) cholesterol levels. Prevention could be subdivided into: Primary prevention- (i) initial treatment is diet/exercise and should be given three to six months on dietary therapy prior to beginning medication and longer if lipids are improving and nearing LDL thresholds (ii) obtain cholesterol tests starting at the age of 20 (iii) eat a diet low in total fat, saturated fat, and cholesterol namely eat poultry without the skin, fish, vegetables, most fruits, whole grains, and skim milk (iv) reduce sugar intake (v) eat foods high in soluble fiber (vi) eat more cold water fish and soy products (vii) avoid cigarette smoking (viii) drink alcohol in moderation (two drinks per day for men, one drink per day for women) (ix) avoid overweight (x) exercise regularly and control blood sugar if diabetes is implicated (xi) increase physical activity (xii) consume a diet that contains adequate potassium, calcium, and magnesium to facilitate blood pressure control. Secondary prevention: Measuring lipids in adolescents that have strong family history of two or more coronary heart disease risk factors. In summary, US National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III in its guidelines has communicated the importance of early identification of risk, lifestyle modification, and pharmacologic treatment as the mainstay of therapy for hyperlipidemia and in the prevention of cardiovascular-related death.

The Promise of Nigeria Natural Products: Since the recognition of hyperlipiermia, a large number of plant species have been identified as having antihyperlipidermic properties and natural products are part of the current therapy for hyperlipidermia. Numerous natural products with antihyperlipidemic effect have been described in the literature. The objective of this chapter is to summarize the role of Nigeria natural products in the treatment and prevention of hyperlipidermia to date and to highlight specific classes of compounds that possess a requisite level of activity that would be considered worthy of further investigation as potential drug candidate.

3. Discussion

3.1. Antilipidemic agents from Nigeria flora

In Nigeria, traditional medicine has been the most popular means of healthcare from the olden days, before the emergence of alternative medicine in the form of synthetic agents. Traditional medicine can be said to be indigenous and a culture handed over to us by our anscestors as a means of surviving from various ailment obvious in every society. Due to high cost of synthetic drugs and side effects, natural products have become the best alternative strategy for the development of safe antilipidemic drugs. Various natural products both crude and isolated components found from plants are effective remedies for hyperlipidemia cases. Several proves are available in nature, indicating the positive effects of many natural product components that can be employed for the treatment of hyperlipidemia. Ibrahim et al, 2013 stated that polyphenols as apigenin, genistein and catechins as well as saponins, sterols, stanols polyunsaturated fatty acids, mucilage and carbohydrates are good examples of agents found to exhibit potent hypocholesterolemic activities. Table3 summarizes the continuous investigations of Nigerian plants used as antihyperlipidemia from ethnopharmacological approach based on the folkloric claims.

Sources Morphological parts Comments References
Persea American (Avocado pea)Leaves, methanolic extractHypolipidemic activity at 40 mg/kg Kolawole et al., 2012
Garcinia kola Root and seed, normal saline extractsHypolipidemic activity at 300-900 mg/kgUdenze et al., 2012
Viscum album Plant parts, methanolic extractHypolipidemic activity at 50-100 mg/kgOluwatosin et al., 2012
Carica papaya Seed, aqueous extractHypolipidemic activity at 100-400 mg/kgNwangwa and Ekhoye 2013
Emila praetermissa Leaves, aqueous extractHypolipidemic activityAnaka et al., 2013
Cleistopholis patensLeaves, aqueous extractHypolipidemic activity at 400-600 mg/kgUdem et al., 2011
Solanum anguivi,
S. macrocarpum
Fruit, aqueous extractHypolipidemic activity at 20-100 mg/kgElekofehiniti et al. 2012; Sodipo et al., 2011
Annona muricata Plant parts, methanolic extractHypolipidemic activity Adeyemi et al., 2009
Nauclea latifolia Root and stem bark, ethanolic extractHypolipidemic activity at 100-150 mg/kgOdey et al., 2013
Acalypha torta
A. capitata
Leaves, aqueous extractHypolipidemic activity at 100-200 mg/kgNnodim et al, 2011
Scoparia dulcis Plant (herb) parts, methanolic extractHypolipidemic activityOrhue and Nwanze, 2006
Alchornea cordifolia Leaves, butanolic extractHypolipidemic activity at 800 mg/kgMohammed et al., 2012
Vernonia amygdalina
Vernonia amygdalina
Plant parts, methanolic extract; Leaves, ethanolic extract; root, normal saline extractHypolipidemic activity
Hypolipidemic activity at 100-200 mg/kg
Oluwatosin et al., 2008
Igbakin 2009, Owen et al., 2011
Moringa oleiferaLeaves, aqueous extractHypolipidemic activity at 1 mg/gGhasi et al., 2000
Clerodendrum capitalum Leaves, aqueous extractHypolipidemic activity at 100-800 mg/kgAdenaya et al., 2008
Parkia biglobosa Plant parts, methanolic extractHypolipidemic activity at 30-60 mg/kgOdetola et al., 2006
Citrus paradisi Seed, methanolic extractHypolipidemic activity at 100-600 mg/kgAdeneye, 2008
Cymbopogon citrates Leaves, aqueous extractHypolipidemic activity at 125-500 mg/kgAdeneye & Agbaje, 2007
Catharanthus roseus Leaves, aqueous extractHypolipidemic activity at1 ml/kgAntia & Okokon, 2005
Albizzia chevalieri Root, aqueous extractHypolipidemic activity at 100-300 mg/kgSaidu et al., 2010
Stachytarphela augustifolia Aerial part, methanolic extractHypolipidemic activity Garba et al., 2013
Vitex doniana Leaves, ethanolic extractHypolipidemic activityOche et al., 2012
Morinda morindoides Root bark, methanolic extractHypolipidemic activityOlukunle et al., 2012
Arachis hypogaea Plant parts, aqueous extractHypolipidemic activity at 175 mg/kgBilbis et al., 2002
“Ata-Ofa’ (polyherbal tea)Leaves, methanolic extractHypolipidemic activity at 50 mg/kgAtawodi, 2001
Xylopia aethiopica Seed, methanolic extractHypolipidemic activity at 250 mg/kgNwozo et al., 2011
Parinari polyandra Fruit, ethanolic extractHypolipidemic activity at 50-250 mg/kgAbolaji et al., 2007
Telfairia occidentalisPlant parts,
methanolic extract
Hypolipidemic activity Adaramoye et al., 2007
Curcuma longa
methanol extract of the
hypoglycemic and hypolipidemic acitivity 100 mg/kgNwozo et al, 2009.
Spondia mombia Aqueous leave extractLipid lowering effect at the doses of 250, 500and 750 mg/kg
Igwe et al, 2008
Croton zambesicus Ethanolic leaf extractLipid lowering effectOfusori et al, 2012.
Momordica charantia Linn Methanolic extract of the fruitsAnti-Diabetic and Hypolipidemic Effects at the doses of 200, 400 and 600 mg/kg Kolawole and Ayankunle, 2012.
Bauhinia thoningii Aqueous crude extractHypoglycemic and lipidemic effecteOjezele and Abatan, 2011.
Cajanus cajan Methanolic leaf extractAntioxidant and hypolipidemic activity at the dose of 200 mg/kgAkinloye and Solanke 2011.
Jatropha tanjorensis Methanolic leaf extractSerum lipid profile and phytochemical composition at 100, 200 and 500mg/kg dose ranges
Oluwole et al, 2011.
Melanthera scandens Ethanolic leaf extractAntidiabetic and hypolipidemic activities at the doses of 37, 74 &111 mg/kgAkpan et al, 2012.
Ricinus communis Aqueous root extract Hypoglycaemic potential, lipid profile effects At a dose of 500mg/kgMatthew et al, 2012.

Table 3.

Medicinal plants investigated in Nigeria for use as Antihypolipidemic agent

These plants have been identified, authenticated and investigated from Nigeria flora against hyperlipidemia, using pharmacological validated animal models. They all have levels and with some levels of increase in LDL, TC, TG and decrease in HDL. Furthermore, there has been recent interest on the research towards hyperlipidemia due to its obvious relationship with diabetes and other ailments like cushing’s syndrome, renal disorder, pregnancy, polycystic ovary syndrome, underactive thyroid gland etc. Hyperlipidemia arising from high serum triglyceride or total cholesterol concentration or both has been reported in diabetic and hypertensive patients. Diabetics have been reported to be more prone to cardiovascular diseases including hypertension than non-diabetics (Bilbis et al, 2002). An overview of 40 medicinal plant species from Nigerian indigenous plants reported to have hypolipidemic effects are presented. Most of the reported hypolipidemic effects were on crude extracts and active constituents. Above 30 % of the investigated plant parts had effects on both lipid profile and glyceamic index. However, much still needs to be done on several phytoconstituents of these plants, as well as conduct clinical research on active constituents derived from them, especially in the determination of their levels of toxicity. Other Nigerian plants claimed to have positive effects on lipid profile but found to act as soup thickeners are yet to be investigated. The reported Nigerian plants in Table 3 are rich in soluble and dietary fibres ( examples, legumes, fruits and vegetables) and if found to have minimal toxicities, can be incorporated into dietary supplements. According to Ibrahim et al, (2013), the major advantage of natural hypolipidemic drugs over synthetic drugs is that many natural drugs exhibit their hypolipidemic activity by different mechanisms. Plants are known to have a striking potential in the management of lipid metabolism and providing better therapeutic effects as an alternative medicine.

4. Conclusion

The use of herbal or natural medicines for the treatment of various disorders has a long and extensive history. The reported plants have the potential to act as lipid-lowering agents with minimal side effects (advantage over currently synthetic drugs) and thus could find their way onto the world market as alternatives to prescribed drugs currently available to treat hyperlipidermia. Most of the studies were carried out with crude extract and administered orally. The principal families in which such activity has been reported are Acanthaceae, Apiaceae, Asteraceae, Azoaceae, Combretaceae, Cucurbitaceae, Euphorbiaceae, Fabaceae, Lamiaceae, Liliaceae, Malvaceae, Myrtaceae, Rubiaceae, Rutaceae and Zingiberaceae, Finally, all the plant species appear to be promising as hypolipidemic agents with activity mediated through various mechanisms.


1 - A. O Abolaji, A. H Adebayo, O. S Odesanmi, 2007Effects of Parinari polyandra (Rosaceae) on serum lipid profile and some electrolytes in pregnant rabbits. Res. J. of Med.Plant 14121127
2 - O. A Adaramoye, J Achem, O. O Akintayo, M. A Fafunso, 2007Hypolipidemic effect of Telfairia occidentalis (fluted pumpkin) in rats fed a cholesterol-rich diet. J Med Food. 1023306
3 - A. A Adeneye, T. I Adeleke, A. K Adeneye, 2008Hypoglycemic and hypolipidemic effects of the aqueous fresh leaves extract of Clerodendrum capitatum in Wistar rats. J. Ethnopharmacol 1161710
4 - A. A Adeneye, 2008Hypoglycemic and hypolipidemic effects of methanol seed extract of Citrus paradisi Macfad (Rutaceae) in alloxan-induced diabetic Wistar rats. Nig Q J Hosp Med.; 1842115
5 - A. A Adeneye, E. O Agbaje, 2007Hypoglycemic and hypolipidemic effects of fresh leaf aqueous extract of Cymbopogon citratus Stapf. in rats. J. Ethnopharmacol. 25;11234404
6 - A. A Adeneye, A. J Olagunju, 2009Preliminary hypoglycemic and hypolipidemic activities of the aqueous seed extract of Carica papaya. Biology and Medicine 1
7 - O Aderamoye, M Amanlou, M Habibi-rezaei, P Pasalar, M. M Ali, 2012Methanolic extract of African mistletoes (Viscum album) improves carbohydrate metabolism and hyperlipidemia in streptozotocin-induced diabetic rats. Asian Pac J. Trop. Med. 5642733
8 - D. O Adeyemi, O. A Komolafe, S. O Adewole, E. M Obuotor, 2009Anti-hyperlipidemic activities of Annona muricata (Linn). Int. J.Altern. Med. 7DOI:b
9 - O. A Akinloye, and O. O Solanke, 2011Evaluation of hypolipidemic and potential antioxidant effects of Pigeon pea (Cajanus cajan (l) mill sp.) leaves in alloxan-induced hyperglycemic rats. J. of Med. Plants Res. 525212524
10 - E. J Akpan, J. E Okokon, E Offong, 2012Antidiabetic and hypolipidemic activities of ethanolic leaf extract and fractions of Melanthera scandens. Asian Pacific J. of Tropical Biomedicine, 523527
11 - S. A Akuyam, P. O Anya, H. S Isah, I. S Aliyu, R Yusuf, 2010Lipid abnormalities: “A Case Study of Ahadu Gello University Hospital, Zaria, Nigeria”. Ann. Nig. Med. 41013
12 - Alli Smith YRAdenlawo IG, 2013Tissue lipid profile of rats administered saponin extract from the root of bitter kola. Adv, in Biochem., 1114
13 - American Diabetes Association2001Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 24:S44S47.
14 - Anaka Ogochukwu NgoziOwolabi Omonkhelin Josephine, EmenikeChinwendu, 2013Anti-hyperlipidemic effect of aqueous leaf extracts Emilia praetermissa niline-redh (Asteraceae) in rats. Inter J, of Biosciences. 356877
15 - B. S Antia, J. E Okokon, 2005Effect of leaf juice of Catharanthus roseus Linn on cholesterol, triglyceride and lipoproteins levels in normal rats. Indian J Pharmacol. 374012
16 - S. E Atawodi, 2011Evaluation of the hypoglycemic, hypolipidemic and antioxidant effects of methanolic extract of “Ata-Ofa” Polyherbal Tea (A-Polyherbal) in Alloxan-induced diabetic rats. Drug Invention Today. 311270276
17 - L. S Bilbis, R. A Shehu, M. G Abubakar, 2002Hypoglycemic and hypolipidemic effects of aqueous extract of Arachis hypogaea in normal and alloxan-induced diabetic rats. Phytomedicine 965535
18 - H. M Burkill, 1997The useful plants of west tropical Africa. 2. 4Roya Botanic Gardens, kew.
19 - A Chait, J. D Brunzell, 1990Acquired hyperlipidemia (secondary dyslipoprotein-emias). Endocrinol Metab Clin North Am. 19259278
20 - L. B Dixon, N. D Ernst, 2001Choose a diet that is low in saturated fat and cholesterol and moderate in total fat:subtle changes to a familiar message. J. Nutr. 131(2S-1):510S-526S
21 - B. A Duplaga, 1999Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors. Ann. Pharmacother; 331112241227
22 - O. O Elekofehinti, I. G Adanlawo, J. A Salin, S. A Sodehinde, 2012Saponins from Solanum anguivi fruits extracts hypolipidemic potential in Rattusnovergicus. Der Pharmacia Lettre. 43811814
23 - Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on DetectionEvaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Jama 20012851924862497
24 - C. N Ezekwesili, O Obidoa, Nwodo OFC, 2008Effect of ethanol extract of Acalypha torta leaves on the lipid profile and serum electrolytes of rabbits. Nig. J. of Biochem. Mol. Bio., 2311521
25 - B Fletcher, K Berra, P Ades, et al2005Managing blood lipids: a collaborative approach. Circulation.11231843209
26 - A Garba, S. B Mada, G Ibrahim, Dauran IA Hamza AB, 2013Studies on hypoglycemic and hypolipidemic effects of methanolic extract of Stachytarpheta angustifolia(mill) in streptozotoin induced diabetic rats. Asian J. Bio. Sci. Doi:10.3923/ajbs.2013
27 - S Ghasi, E Nwobodo, J. O Ofili, 2000Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam in high-fat diet fed wistar rats. J. Ethnopharmacol. 692125
28 - T Gordon, W. P Castelli, M. C Hjortland, et al1977High density lipoprotein as a protective factor against coronary artery disease: the Framingham Study. Am J Med. 6270714
29 - S. M Grundy, 1998Hypertriglyceridemia, atherogenic dyslipidemia and the metabolic syndrome. Am. J. Cardiol. 81:18B-25B.
30 - F. N Hepper, 1963Emilia in: Hutchinso JJ. and Dalziel JM. (eds) Flora of West Tropical Africa, 2nd ed. Crown Agents for Overseas Governments and Administrations, London, Uk. 2244245
31 - A. P Igbakin, 2009Comparative studies on hypoglycaemic, hypoproteinaemic, hypocholesterolaemic and hypolipidaemic properties of ethanolic and normal saline extracts of the root of V. amygdalina in diabetic rats. Adv. Enviro. Bio. 313338
32 - C. U Igwe, O. A Ojiako, L. A Nwaogu, Onyeze, GOC, 2008Lipid Lowering Effect of Aqueous Leaf Extract Of Spondias Mombin Linn J. of Pharmacol. 6 (1) 10
33 - W Insull, 2006Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J.; 99325773
34 - R. H Knopp, 1999Drug treatment of lipid disorders. N. Engl. J. Med. 341498511
35 - O. T Kolawole, S. O Kolawole, A. A Ayankunle, I. O Olaniran, 2012Methanolic leaf extract of Persea americana protects rats against cholesterol-induced hyperlipidemia. British J. of Med. Medical Res., 2223542
36 - O. T Kolawole, and A. A Ayankunle, 2012Seasonal Variation in the Anti-Diabetic and Hypolipidemic Effects of Momordica charantia Fruit Extract in Rats European Journal of Medicinal Plants 22177185
37 - R. M Krauss, 1982Regulation of high density lipoprotein levels. Med. Clin. North. Am. 6640330
38 - R. M Krauss, R. H Eckel, B Howard, L. J Appel, S. R Daniels, R. J Deckelbaum, et al2003AHA Dietary guidelines: Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000:102(18):2284-99.
39 - L Lipka, Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc Drug Rev. 214293312
40 - J Mckenney, 2003Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm.60109951005
41 - R. K Mohammed, S Ibrahim, S. E Atawodi, E. D Eze, J. B Suleiman, I. S Malgwi, 2012The study of the effects of n-butanol fraction of Alchornea cordifolia leaf extract on lipid profile and liver enzymes in streptozotocin-induced diabetic rats. Global Journal of medicinal Plant Research. 1117
42 - E Moutzouri, A Kei, M. S Elisaf, H. J Milionis, 2010Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag. 6525539
43 - E. K Nwangwa, E. I Ekhoye, 2013Anti-hyperlipidemic Activity of aqueous extracts of Carica papaya seeds in albino rats fed with high fat diet. Current Trends in Technology and Science, Vol.II, 2279.
44 - S Nwozo, O Adaramoye, E Ajaiyeoba, 2009Oral Administration of Extract from Curcuma longa Lowers Blood Glucose and Attenuates Alloxan-Induced Hyperlipidemia in Diabetic Rabbits, Pakistan Journal of Nutrition 85625628
45 - S. O Nwozo, Orojobi BF Adaramoye OA, 2011Hypolipidemic and antioxidant potentials of Xylopia aethiopica seed extract in hypercholesterolemic rats. J. Med.Food 14(1-2) 114-19.
46 - A. A Odetola, O Akinloye, C Egunjobi, W. A Adekunle, A. O Ayoola, 2006Possible antidiabetic and antihyperlipidaemic effect of fermented Parkia biglobosa (JACQ) extract in alloxan-induced diabetic rats. Clin. Exp. Pharmacol. Physiol. 33980812
47 - M. O Odey, J. T Johnson, I. A Iwara, B Gauje, N. S Akpan, U. O Luke, A. E Robert, K. M Ukpong, 2012Effect of anti-hypertensive treatment with root and stem bark extracts on Nauclea latifolia on serum lipid profile. G.J.P. and A. Sc. and Tech., 02147884
48 - D. A Ofusori, O. A Komolafe, O. S Adewole, E. M Obuofor, J. B Fakunle, A. O Ayoka, 2012Effect of ethanolic leaf extract of Croton zambesicus (Mull arg.) on lipid profile in streptozotocin-induced diabetic rat. Diabetologia croatica. 412
49 - O. C Oguejiofor, C. H Onwukwe, C. U Odenigbo, 2012Dyslipidemia in Nigeria: “Prevalence and pattern”, (Review). Ann. African Med. 11(4), 197-202.
50 - M. O Ojezele, O. M Abatan, 2011Hypoglycaemic and coronary risk index lowering effects of Bauhinia thoningii in alloxan induced diabetic rats. Afr. Health Sci. 111859
51 - Okpe OcheAbdullahi Salman A, Nkeonye Ogechi L, Ilechukwu Chijioke C, Nweke Ogechi, Ihuoma Onyeyirichi, 2012Hypoglycemic and hypolipidemic Effects of aqueous and ethanolic leaf extracts of Vitex doniana (Verbenaceae) in normoglycemic albino rats. Global Advanced Research Journal of Microbiology 1173179
52 - J. O Olukunle, M. O Abatan, O. T Adenubi, T. A Amusan, 2012Hypoglycaemic and hypolipidaemic effects of crude extracts and chromatographic fractions of Morinda morindoides root bark in diabetic rats. Acta Vet. Brno. 8126974
53 - A Oluwatosin, Adaramoye, Olajumoke Akintayo, Jonah Achem, Michael A, Fafunso, 2008Lipid-lowering effects of methanolic extracts of V. amygdalina leaves in rats fed on high cholesterol diet. J. Am. Med. Assoc. 25135164
54 - I Oluwole, Oyewole1 and Peter F. Akingbala, 2011Phytochemical Analysis and Hypolipidemic Properties of Jatropha tanjorensis Leaf Extract Eur. J.l of Med. Plants1(4): 180-185,
55 - OrhueNEJ and Nwanze, EAC, 2006Scoparia dulcis reduces the severity of trypanosome brucei-induced hyperlipidaemia in the rabbit. Afr. J. of Biotech. 5883887
56 - C. U Osuji, B. A Nzerem, S Meludu, C. E Dioka, E Nwobodo, G. I Amilo, 2010The prevalence of over weight/obesity and dyslipidemia amongst a group of women attending “August” meeting. Nig. Med. J. 51(4), 155-159.
57 - C Out, A. K Groen, G Brufau, 2012Bile acid sequestrants: more than simple resins. Curr Opin. Lipidol. 2314355
58 - O. J Owen, Amakiri AOA, Karibi-Botoye TA, 2011Lipid-lowering effects of bitter leaf in boiler chickens fed finishers’ mash. Agr. Bio. J. North Am. 21517525
59 - S. B Patel, 2004A novel cholesterol-lowering agent that highlights novel physiologic pathways. Curr. Cardiol. Rep. 643942
60 - J Pieper, 2003Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am. J. Health Sys. Pharm. 60(13 suppl 2): S9S14.
61 - N Prabhjot, F Burke, A Bloesch, D Rader, 2010Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J. Clin. Lipidol. 424858
62 - G Ram, D Becker, 2011The role of red yeast rice for the physician. Curr. Atheroscler. Rep.137380
63 - R. M Sabrin, G. A Ibrahim, Z. M Mohamed, K. M Banjar, 2013Natural antihyperlipidemic agents: Current and future perspectives. Phytopharmacol. 43492531
64 - R. S Safeer, C. L Lacivita, 2000Choosing drug therapy for patients with hyperlipidemia. Am. Fam. Physician 6111337182
65 - Y Saidu, F. C Nwachukwu, L. S Bilbis, U. Z Faruk, and A. Y Abbas, 2010Hypoglycaemic and hypolipidemic Effects of root extracts of Albizzia chevalieri in alloxan induced diabetic rats. Nig. J. Basic and Appl. Sci. 1817278
66 - R Shamir, E. A Fisher, 2000Dietary therapy for children with hypercholesterolemia. Am Fam. Physician. 61367585
67 - O A Sodipo, F. I Abdulrahman, U. K Sandabe, 2011Total lipid profile, faecal cholesterol, very low density lipoprotein cholesterol (VLDL-C), atherogenic index (A.I) and percent atherosclerosis with aqueous fruit extract of Solanum macrocarpum in chronic troton-induced hyperlipidemic albino rats. Current Res. J.Bio. Sci. 422026214
68 - N. J Stone, 1994Secondary causes of hyperlipidemia. Med. Clin. North. Am. 78117141
69 - N. J Stone, 2001The optimal dietary strategy to manage risk associated with various dyslipidemias. Curr. Cardiol. Rep. 3391400
70 - S Tenhola, A Martikainen, E Rahiala, E Herrgard, P Halonen, R Voutilainen, 2000Serum lipid concentrations and growth characteristics in 12-year-old children born small for gestational age. Pediatr. Res. ;48562328
71 - P Toth, T Dayspring, G Pokrywka, 2009Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. Curr. Atheroscler. Rep.117179
72 - S. C Udem, U. C Ezeonuegbu, R. I Obidike, 2011Experimental studies on the hypolipidemic and haematological properties of aqueous leaf extract of Cleistopholiss patens Benth & Diets. (Annonacae) in hypercholesterolemic rats. Ann. Med. Health Sci. Res. (1): 115-21
73 - Udenze ECCBraide VB, Okwesilieze CN, Akuodor GC, 2012Pharmacological effects of Garcinia kola seed powder on blood sugar, lipid profile and atherogenic index of alloxan-induced diabetes in rats. Pharmacologia 31269399
74 - R. L Washington, 1999Interventions to reduce cardiovascular risk factors in children and adolescents. Am. Fam. Physician 59221118
75 - World Health Organization and International Diabetes Federation in Europe1989Diabetes care and research in Europe; Saint Vincent Declaration. British Med. J. 299 11981201